SCHEMBL3485749

SCHEMBL3485749

CN(C1CCN(CC(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1)S(=O)(=O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
ALDH1A1 P00352 3/20 0.56
HSD17B10 Q99714 1/20 0.56
L3MBTL1 Q9Y468 3/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
POLB P06746 1/20 0.49
HTR2A P28223 2/20 0.49
HTR2C P28335 2/20 0.49
CACNA1B Q00975 1/20 0.47
DRD4 P21917 1/20 0.47
TSHR P16473 1/20 0.47
TACR1 P25103 1/20 0.47
HTT P42858 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
PKM P14618 1/20 0.46
RECQL P46063 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13541732 0.94 LMNA (0.52) LMNAALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL8234997 0.85 CACNA1B (0.54) LMNAALDH1A1L3MBTL1KDM4EMAPT
SCHEMBL3484953 0.85 L3MBTL1 (0.61) LMNAALDH1A1L3MBTL1KDM4EMAPT
SCHEMBL3485780 0.85 POLB (0.55) LMNAALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL3485838 0.83 TSHR (0.58) LMNAALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL3486011 0.82 ALDH1A1 (0.57) LMNAALDH1A1HSD17B10KDM4EMAPT
SCHEMBL3485746 0.81 ALDH1A1 (0.56) LMNAALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL3485714 0.81 DRD4 (0.50) LMNAALDH1A1HSD17B10L3MBTL1MAPT
SCHEMBL3485577 0.80 TSHR (0.46) LMNAALDH1A1HSD17B10MAPTSMN1; SMN2
SCHEMBL3485937 0.79 ALDH1A1 (0.50) LMNAALDH1A1HSD17B10KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US claimed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B LMNA 1608/4885ALDH1A1 2210/4885HSD17B10 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.